New Commentary Weighs the Real-World Impact of the First Biosimilar Insulin Glargine

When the first biosimilar version of insulin glargine entered the United States market, it carried with it the promise that has defined the broader biosimilar experiment: that near-identical copies of complex biologic medicines could finally break the grip of high drug prices on one of the most essential therapies in modern medicine. A new letter to the editor published in the Journal of General Internal Medicine by S. Dhanya Dedeepya, Vaishali Goel, and Nivedita Nikhil Desai now adds a critical voice to the conversation surrounding that promise, responding directly to a real-world data study by Watanabe and colleagues that examined insulin glargine utilization and spending before and after the introduction of the first biosimilar insulin glargine.

The original study, published online in November 2025 in the same journal, used real-world data to track how clinicians and patients actually behaved once a biosimilar alternative to the long-acting insulin analog became available. Real-world data studies of this kind occupy a crucial middle ground between randomized controlled trials and everyday clinical practice. Trials can establish that a biosimilar is therapeutically equivalent to its reference product, but they cannot fully capture how prescribing habits, formulary decisions, rebate negotiations, pharmacy benefit designs, and patient cost-sharing arrangements shape uptake in the messy reality of the American health system. The letter writers engage with exactly this gap, using their comment to probe what the utilization and spending patterns observed in the data actually reveal about whether biosimilar competition is delivering on its economic promise.

Insulin glargine is a long-acting basal insulin analog that has been a cornerstone of diabetes management for millions of people with type 1 and type 2 diabetes. As a biologic medicine, it is produced in living cell systems rather than through straightforward chemical synthesis, which means that even a functionally identical copy cannot be a molecular clone in the way a generic small-molecule drug can. Biosimilars are instead demonstrated to be highly similar to their reference products, with no clinically meaningful differences in safety, purity, or potency. This regulatory framework, established in the United States through the Biologics Price Competition and Innovation Act of 2010, was designed to open the door to competition while maintaining rigorous scientific standards. The arrival of the first biosimilar insulin glargine was therefore watched closely as a test case for whether the framework could translate regulatory approval into real savings at the pharmacy counter.

The stakes of this question are difficult to overstate. Insulin pricing in the United States has been the subject of sustained public outrage, legislative hearings, and policy reform efforts for more than a decade. List prices for analog insulins rose dramatically over the 2000s and 2010s, forcing many patients to ration doses, and the resulting human toll made insulin the emblematic case study of pharmaceutical pricing dysfunction. Biosimilars were held up by policymakers and health economists as one of the most credible market-based levers for change, because unlike price negotiation or direct regulation, they promised to lower prices through the familiar mechanism of competition. Whether that mechanism actually functions for biologics, where switching behavior is slower, prescriber inertia is stronger, and rebate structures can lock in incumbent products, is precisely the empirical question the original study addressed.

The commentary authors, based at institutions in India including Saveetha Medical College and Hospital in Chennai, Graphic Era Hill University in Dehradun, and Dr. D. Y. Patil Medical College in Pune, bring a pharmacoeconomic and global health perspective to the debate. Their letter engages with the methodological choices embedded in the original real-world analysis, and their response reflects a broader international interest in how biosimilar policy performs in the world’s largest pharmaceutical market. The authors report no funding for their work and declare no conflicts of interest, and they note that no new data were generated or analyzed in the comment itself, positioning it squarely as an interpretive and critical contribution to the literature rather than a new empirical study.

One of the central tensions in biosimilar economics is the distinction between list price and net price. When a biosimilar launches at a lower list price than the reference biologic, headlines often celebrate the discount. Yet the net price paid by insurers and patients is shaped by a web of rebates that manufacturers of the originator product offer to pharmacy benefit managers and health plans. These rebate arrangements can make the originator product cheaper for a plan’s formulary than the nominally cheaper biosimilar, a phenomenon that has been documented across several biologic drug classes. Real-world utilization data, such as those analyzed in the original study, are therefore essential for cutting through this opacity, because actual dispensing patterns reveal whether the biosimilar is genuinely displacing the originator or merely occupying a marginal share of the market.

Prescriber and patient behavior adds a second layer of complexity. Decades of research on generic substitution show that even for chemically identical small-molecule drugs, switching rates depend heavily on prescriber trust, electronic health record defaults, pharmacy-level substitution laws, and patient familiarity with a brand name. For biosimilars, the psychological barriers can be even higher, because patients may perceive a biologic copy as somehow less reliable than the original, and clinicians may harbor questions about immunogenicity or device differences even when regulatory data show equivalence. The pace of biosimilar insulin glargine uptake observed in real-world data thus reflects not only price dynamics but also the slow work of building clinical confidence in a new category of medicine.

The letter also situates the insulin glargine case within the wider arc of biosimilar policy. In Europe, where biosimilar uptake was encouraged earlier through national policies, tendering systems, and physician education campaigns, several biologic markets saw substantial price erosion and high biosimilar penetration within a few years of launch. The United States experience has been more uneven, with uptake varying dramatically by drug class, by payer type, and by the design of pharmacy benefit incentives. Comparing the American insulin glargine trajectory against these international benchmarks is one of the analytical lenses through which commentaries like this one help readers judge whether slow uptake is an inevitable feature of a fragmented system or a policy failure that could be corrected with better incentives.

What makes this exchange between the original researchers and the commenting authors scientifically valuable is that it exemplifies the self-correcting machinery of health services research. Real-world data studies rely on large claims databases and utilization records, and the interpretation of spending trends in such data is sensitive to choices about study windows, comparator groups, adjustments for rebate-driven price changes, and the treatment of patients who switch between products. A letter to the editor is a formal venue for surfacing those interpretive choices, questioning whether observed spending changes can be causally attributed to biosimilar entry, and proposing alternative readings of the same evidence. The published reply and the surrounding dialogue allow the field to converge on more robust conclusions than any single analysis could deliver alone.

As insulin policy in the United States enters a new phase, with out-of-pocket caps for Medicare beneficiaries, manufacturer price reductions, and continued biosimilar entries reshaping the landscape, the questions raised in this commentary will only grow in importance. The first biosimilar insulin glargine was a landmark test of whether competition can discipline biologic drug prices, and the real-world evidence examined by Watanabe and colleagues, together with the critical scrutiny it has attracted, suggests that the answer is neither a simple success nor a simple failure. Savings appear to depend on the fine print of formulary design, rebate negotiations, and the behavioral economics of prescribing. For the millions of patients who depend on basal insulin, and for the policymakers designing the next generation of drug pricing reforms, the lesson of this scholarly exchange is that regulatory approval of a biosimilar is only the beginning of the story; the economics of competition must be actively engineered, monitored, and debated in the open, one peer-reviewed analysis at a time.

Subject of Research: Real-world utilization and spending outcomes of the first biosimilar insulin glargine

Article Title: Comment on “Insulin Glargine Utilization and Spending Before and After the First Biosimilar Insulin Glargine: A Real-World Data Study”

Article References: Comment on “Insulin Glargine Utilization and Spending Before and After the First Biosimilar Insulin Glargine: A Real-World Data Study”. (n.d.). https://doi.org/10.1007/s11606-026-10834-4

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10834-4

Keywords: insulin glargine, biosimilars, drug pricing, pharmacoeconomics, type 2 diabetes, real-world data, health policy, biologics, prescription drug spending, Journal of General Internal Medicine, pharmacy benefit design, diabetes care